Kura Oncology, Inc. KURA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Kura Oncology, Inc. (KURA) is a healthcare company listed in the US with a market value of about $714M. In the twelve months to September 30, 2026 it had revenue of $79M and net income of -$293M, a net margin of -369.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -58%.
About Kura Oncology
Kura Oncology is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 31% over three years (dilution for shareholders). It spends 372% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79M | $67M | $54M | $0 | — | — | — | — | — | — | — |
| Net income | -$293M | -$279M | -$174M | -$153M | -$136M | -$130M | -$90M | -$63M | -$60M | -$35M | -$28M |
| Free cash flow | -$89M | -$71M | $134M | -$125M | -$111M | -$106M | -$72M | — | — | — | — |
| EPS (diluted) | $-3.30 | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 | $-1.51 | $-1.72 | $-1.52 | $-1.47 |
| Net margin | -369.3% | -413.0% | -322.9% | — | — | — | — | — | — | — | — |
| ROIC | — | -123.3% | -35.5% | -40.0% | -32.2% | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $32.00, 312% above the current price; targets range from $15.00 to $76.00; the consensus rating is “Strong buy”; expected EPS is $-3.21 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Kura Oncology pay a dividend?
Not currently.
Is Kura Oncology a good stock to buy?
We do not give buy or sell advice. Kura Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.